Journal of Clinical Oncology, Vol 10, 657-670, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer [published erratum appears in J Clin Oncol 1992 Oct;10(10):1655-8]

DM Eddy
Center for Health Policy, Research, and Education, Duke University, Durham, NC.

PURPOSE: This review was undertaken to examine the evidence of effectiveness of high-dose chemotherapy and autologous bone marrow transplantation (HDC/ABMT) for the treatment of metastatic breast cancer and to compare the magnitudes of the benefits and harms of HDC/ABMT with those of conventional doses of chemotherapy. DESIGN: Published studies were reviewed and analyzed. RESULTS: No randomized controlled trials have been published that evaluate HDC/ABMT. Only one internally controlled study has been conducted; it demonstrated that HDC/ABMT and conventional treatment have virtually identical outcomes. Comparisons of uncontrolled clinical series are confounded by patient selection and other biases. Gross comparisons indicate that, compared with conventional-dose chemotherapy, HDC/ABMT achieves (1) higher complete response rates (36% v 8%), (2) higher overall response rates (70% v 39%), (3) similar median response durations (8 months v 9.6 months), (4) similar median survival durations (16 months v 16.6 months), and (5) similar overall survival rates (eg, 43% 2-year survival v 39%). Observations of cases with longer-term disease-free survival are promising but not conclusive. High-dose chemotherapy with ABMT has a higher treatment-related mortality rate (5% to 15% v 1%), a high rate of nonmortal toxicity (approximately 30%), and a high rate of side effects (approaching 100%). CONCLUSIONS: Firm conclusions are not possible because of the lack of controlled studies and the presence of numerous biases. However, the existing evidence does not demonstrate that HDC/ABMT is superior to conventional-dose chemotherapy for the treatment of metastatic breast cancer. Randomized controlled trials are needed.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up Ann. Onc., June 1, 2008; 19(6): 1082 - 1089. [Abstract] [Full Text] [PDF]

				P. D. Jacobson, R. A. Rettig, and W. M. Aubry Litigating the Science of Breast Cancer Treatment Journal of Health Politics Policy and Law, October 1, 2007; 32(5): 785 - 818. [Abstract] [PDF]

				A.R. Zander, N. Kroger, C. Schmoor, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. Schultze, W.E. Berdel, M. Koenigsmann, et al. High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial J. Clin. Oncol., June 15, 2004; 22(12): 2273 - 2283. [Abstract] [Full Text] [PDF]

				M. Gurevich, G. M. Devins, and G. M. Rodin Stress Response Syndromes and Cancer: Conceptual and Assessment Issues Psychosomatics, August 1, 2002; 43(4): 259 - 281. [Abstract] [Full Text] [PDF]

				H G. Welch and J. Mogielnicki Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer BMJ, May 4, 2002; 324(7345): 1088 - 1092. [Full Text] [PDF]

				M. M. Mello and T. A. Brennan The Controversy Over High-Dose Chemotherapy With Autologous Bone Marrow Transplant For Breast Cancer Health Aff., September 1, 2001; 20(5): 101 - 117. [Abstract] [Full Text] [PDF]

				W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer Oncologist, February 1, 2000; 5(1): 1 - 13. [Abstract] [Full Text]

				D. L. Carter, L. B. Marks, J. M. Bean, G. Broadwater, A. Hussein, J. J. Vredenburgh, W. P. Peters, and L. R. Prosnitz Impact of Consolidation Radiotherapy in Patients With Advanced Breast Cancer Treated With High-Dose Chemotherapy and Autologous Bone Marrow Rescue J. Clin. Oncol., March 1, 1999; 17(3): 887 - 887. [Abstract] [Full Text] [PDF]

				C. L. Vogel and J.-M. Nabholtz Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents Oncologist, February 1, 1999; 4(1): 17 - 33. [Abstract] [Full Text]

				L. R. Acuna, M. Langhi, J. Perez, J. R. Acuna, M. Machiavelli, J. Lacava, C. Vallejo, A. Romero, H. Fasce, E. Ortiz, et al. Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer J. Clin. Oncol., January 1, 1999; 17(1): 74 - 74. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi Treatment of Breast Cancer N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984. [Full Text] [PDF]

				J.-P. Droz, S. Culine, P. Biron, and A. Kramar High-Dose Chemotherapy in Adult Solid Tumors and Lymphoproliferative Disorders: The Need for Randomized Trials Oncologist, April 1, 1997; 2(2): 83 - 93. [Abstract] [Full Text] [PDF]

				K. J. Krause, C. M. Cutler, I. S. Udvarhelyi, W. Winkenwerder, J. K. Erban, K. M. Templeton, J. R. Wingard, V. Khanna, W. P. Peters, and M. C. Rogers Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer N. Engl. J. Med., August 4, 1994; 331(5): 329 - 331. [Full Text]

				H. B. Muss, A. D. Thor, D. A. Berry, T. Kute, E. T. Liu, F. Koerner, C. T. Cirrincione, D. R. Budman, W. C. Wood, M. Barcos, et al. c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer N. Engl. J. Med., May 5, 1994; 330(18): 1260 - 1266. [Abstract] [Full Text]

				S. D. Boren I Had a Tough Day Today, Hillary N. Engl. J. Med., February 17, 1994; 330(7): 500 - 502. [Full Text]

				J. A. O'Shaughnessy and K. H. Cowan Dose-Intensive Therapy for Breast Cancer JAMA, November 3, 1993; 270(17): 2089 - 2092. [Abstract] [PDF]

				T. J. Smith Which Hat Do I Wear? JAMA, October 13, 1993; 270(14): 1657 - 1659. [PDF]

				J. R. Beck Making Medical Decision Making More User-friendly Med Decis Making, February 1, 1993; 13(1): 1 - 2. [PDF]

				D. M. Eddy, B. E. Hillner, T. J. Smith, and C. E. Desch High-Dose Chemotherapy With Autologous Bone Marrow Transplantation for Metastatic Breast Cancer JAMA, September 23, 1992; 268(12): 1536 - 1537. [Abstract] [PDF]

				D. M. Eddy Cost-effectiveness Analysis: Will It Be Accepted? JAMA, July 1, 1992; 268(1): 132 - 136. [PDF]

				D. M. Eddy Cost-effectiveness Analysis: Is It Up to the Task? JAMA, June 24, 1992; 267(24): 3342 - 3348. [PDF]